Kezar Life Sciences, Inc. (KZR) Invested Capital (2021 - 2025)

Kezar Life Sciences has reported Invested Capital for 5 years, with the latest figure at $5.3 million in Q3 2025.

• Quarterly Invested Capital rose 34.91% year-over-year to $5.3 million in Q3 2025, while the trailing twelve-month figure through Mar 2026 was $10.6 million (down 37.65% YoY) and the FY2024 annual result came in at $5.2 million, down 47.83% from the prior year.
• Invested Capital held at $5.3 million in Q3 2025 per KZR's latest filing, from $5.3 million in the prior quarter.
• Over five years, Invested Capital peaked at $10.0 million in Q4 2021 and troughed at $1.3 million in Q1 2024.
• A 5-year average of $7.4 million and a median of $10.0 million in 2021 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2024 and 2025: Invested Capital slumped 86.96% in 2024, then jumped 300.08% in 2025.
• Over 5 years, Invested Capital stood at $10.0 million in 2021, then changed by 0.0% to $10.0 million in 2022, then changed by 0.0% to $10.0 million in 2023, then slumped by 47.83% to $5.2 million in 2024, then rose by 1.19% to $5.3 million in 2025.
• According to Business Quant data, Invested Capital over the past three periods registered $5.3 million, $5.3 million, and $5.2 million for Q3 2025, Q2 2025, and Q1 2025 respectively.